Search

Your search keyword '"Devecseri Z"' showing total 18 results
Start Over Author "Devecseri Z"
18 results on '"Devecseri Z"'

1. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis

Author

N’Dow, J., Smith, E.J., Shepherd, R., Ribal, M., Mottet, N., Moris, L., Lardas, M., Willemse, P-P., Gandaglia, G., Campi, R., Nicoletti, Rossella, Gacci, M., Briganti, A., Ratti, M.M., Alleva, E., Leardini, L., Sisca, E.S., Bangma, R., Roobol, M., Remmers, S., Tilki, D., Visakorpi, T., Talala, K., Tammela, T., van Hemelrijck, M., Bayer, K., Lejeune, S., Byrne, S., Fialho, L., De Meulder, P. Palaiologou B., Auffray, C., Hijazy, A., Power, S., Kermani, N. Zounemat, van Bochove, K., Kalafati, M., Moinat, M., Voss, E., Horgan, D., Fullwood, L., Holtorf, M., Lancet, D., Bernstein, G., Omar, I., MacLennan, S., Maclennan, S., Tripathee, S., Wirth, M., Froehner, M., Brenner, B., Borkowetz, A., Thomas, C., Horn, F., Reiche, K., Kreux, M., Josefsson, A., Tandefekt, D. Gasi, Hugosson, J., Huisman, H., Schalken, J., Hofmacher, T., Lindgren, P., Andersson, E., Fridhammar, A., Zong, J., Butler-Ransohoff, J-E., Herrera, R., Maass, M., Torremante, P., Voss, M.D., Devecseri, Z., Abbott, T., Dau, C., Papineni, K., Snijder, R., Lambrecht, M., Wolfinger, R., Rogiers, S., Servan, A., Antoni, L., Pacoe, K., Robinson, P., Jaton, B., Bakkard, D., Turunen, H., Kilkku, O., Pohjanjousi, P., Voima, O., Nevalaita, L., Reich, C., Araujo, S., Longden-Chapman, E., Burke, D., Agapow, P., Derkits, S., Licour, M., McCrea, C., Payne, S., Yong, A., Thompson, L., Mare, S. Le, Bussmann, M, Kotik, D., Siltari, Aino, Lönnerbro, Ragnar, Pang, Karl, Shiranov, Kirill, Asiimwe, Alex, Evans-Axelsson, Susan, Franks, Billy, Kiran, Amit, Murtola, Teemu J., Schalken, Jack, Steinbeisser, Carl, Bjartell, Anders, and Auvinen, Anssi

Published
2023
Full Text
View/download PDF

2. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis

Author

Siltari, Aino, primary, Lönnerbro, Ragnar, additional, Pang, Karl, additional, Shiranov, Kirill, additional, Asiimwe, Alex, additional, Evans-Axelsson, Susan, additional, Franks, Billy, additional, Kiran, Amit, additional, Murtola, Teemu J., additional, Schalken, Jack, additional, Steinbeisser, Carl, additional, Bjartell, Anders, additional, Auvinen, Anssi, additional, N’Dow, J., additional, Smith, E.J., additional, Shepherd, R., additional, Ribal, M., additional, Mottet, N., additional, Moris, L., additional, Lardas, M., additional, Willemse, P-P., additional, Gandaglia, G., additional, Campi, R., additional, Nicoletti, Rossella, additional, Gacci, M., additional, Briganti, A., additional, Ratti, M.M., additional, Alleva, E., additional, Leardini, L., additional, Sisca, E.S., additional, Bangma, R., additional, Roobol, M., additional, Remmers, S., additional, Tilki, D., additional, Visakorpi, T., additional, Talala, K., additional, Tammela, T., additional, van Hemelrijck, M., additional, Bayer, K., additional, Lejeune, S., additional, Byrne, S., additional, Fialho, L., additional, De Meulder, P. Palaiologou B., additional, Auffray, C., additional, Hijazy, A., additional, Power, S., additional, Kermani, N. Zounemat, additional, van Bochove, K., additional, Kalafati, M., additional, Moinat, M., additional, Voss, E., additional, Horgan, D., additional, Fullwood, L., additional, Holtorf, M., additional, Lancet, D., additional, Bernstein, G., additional, Omar, I., additional, MacLennan, S., additional, Maclennan, S., additional, Tripathee, S., additional, Wirth, M., additional, Froehner, M., additional, Brenner, B., additional, Borkowetz, A., additional, Thomas, C., additional, Horn, F., additional, Reiche, K., additional, Kreux, M., additional, Josefsson, A., additional, Tandefekt, D. Gasi, additional, Hugosson, J., additional, Huisman, H., additional, Schalken, J., additional, Hofmacher, T., additional, Lindgren, P., additional, Andersson, E., additional, Fridhammar, A., additional, Zong, J., additional, Butler-Ransohoff, J-E., additional, Herrera, R., additional, Maass, M., additional, Torremante, P., additional, Voss, M.D., additional, Devecseri, Z., additional, Abbott, T., additional, Dau, C., additional, Papineni, K., additional, Snijder, R., additional, Lambrecht, M., additional, Wolfinger, R., additional, Rogiers, S., additional, Servan, A., additional, Antoni, L., additional, Pacoe, K., additional, Robinson, P., additional, Jaton, B., additional, Bakkard, D., additional, Turunen, H., additional, Kilkku, O., additional, Pohjanjousi, P., additional, Voima, O., additional, Nevalaita, L., additional, Reich, C., additional, Araujo, S., additional, Longden-Chapman, E., additional, Burke, D., additional, Agapow, P., additional, Derkits, S., additional, Licour, M., additional, McCrea, C., additional, Payne, S., additional, Yong, A., additional, Thompson, L., additional, Mare, S. Le, additional, Bussmann, M, additional, and Kotik, D., additional

Published
2023
Full Text
View/download PDF

3. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium

Author

Beyer, K., Moris, L., Lardas, M., Omar, M.I., Healey, J., Tripathee, S., Gandaglia, G., Venderbos, L.D.F., Vradi, E., Broeck, T. Van den, Willemse, P.P., Antunes-Lopes, T., Pacheco-Figueiredo, L., Monagas, S., Esperto, F., Flaherty, S., Devecseri, Z., Lam, T.B., Williamson, P.R., Heer, R., Smith, E.J., Asiimwe, A., Huber, J., Roobol, M.J., Zong, J., Mason, M., Cornford, P., Mottet, N., MacLennan, S.J., N'Dow, J., Briganti, A., Huisman, H.J., MacLennan, S., Hemelrijck, M. Van, and Urology

Subjects
Male, Prostatic Neoplasms, Castration-Resistant, Consensus, SDG 3 - Good Health and Well-being, Urology, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Outcome Assessment, Health Care, Humans, Orchiectomy
Abstract

Contains fulltext : 288445.pdf (Publisher’s version ) (Open Access) CONTEXT: Harmonisation of outcome reporting and definitions for clinical trials and routine patient records can enable health care systems to provide more efficient outcome-driven and patient-centred interventions. We report on the work of the PIONEER Consortium in this context for prostate cancer (PCa). OBJECTIVE: To update and integrate existing core outcome sets (COS) for PCa for the different stages of the disease, assess their applicability, and develop standardised definitions of prioritised outcomes. EVIDENCE ACQUISITION: We followed a four-stage process involving: (1) systematic reviews; (2) qualitative interviews; (3) expert group meetings to agree standardised terminologies; and (4) recommendations for the most appropriate definitions of clinician-reported outcomes. EVIDENCE SYNTHESIS: Following four systematic reviews, a multinational interview study, and expert group consensus meetings, we defined the most clinically suitable definitions for (1) COS for localised and locally advanced PCa and (2) COS for metastatic and nonmetastatic castration-resistant PCa. No new outcomes were identified in our COS for localised and locally advanced PCa. For our COS for metastatic and nonmetastatic castration-resistant PCa, nine new core outcomes were identified. CONCLUSIONS: These are the first COS for PCa for which the definitions of prioritised outcomes have been surveyed in a systematic, transparent, and replicable way. This is also the first time that outcome definitions across all prostate cancer COS have been agreed on by a multidisciplinary expert group and recommended for use in research and clinical practice. To limit heterogeneity across research, these COS should be recommended for future effectiveness trials, systematic reviews, guidelines and clinical practice of localised and metastatic PCa. PATIENT SUMMARY: Patient outcomes after treatment for prostate cancer (PCa) are difficult to compare because of variability. To allow better use of data from patients with PCa, the PIONEER Consortium has standardised and recommended outcomes (and their definitions) that should be collected as a minimum in all future studies.

Published
2022

4. Diagnostic and prognostic factors in patients with prostate cancer: a systematic review

Author

Beyer, K., Moris, L., Lardas, M., Haire, A., Barletta, F., Scuderi, S., Molnar, M., Herrera, R., Rauf, A., Campi, R., Greco, I., Shiranov, K., Dabestani, S., Broeck, T. Van den, Arun, S., Gacci, M., Gandaglia, G., Omar, M.I., MacLennan, S., Roobol, M.J., Farahmand, B., Vradi, E., Devecseri, Z., Asiimwe, A., Zong, J., MacLennan, S.J., Collette, L., J, N.D., Briganti, A., Huisman, H.J., Bjartell, A., and Hemelrijck, M. Van

Subjects
Male, Bias, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Humans, Mass Screening, Prostatic Neoplasms, General Medicine, Prognosis
Abstract

ObjectivesAs part of the PIONEER Consortium objectives, we have explored which diagnostic and prognostic factors (DPFs) are available in relation to our previously defined clinician and patient-reported outcomes for prostate cancer (PCa).DesignWe performed a systematic review to identify validated and non-validated studies.Data sourcesMEDLINE, Embase and the Cochrane Library were searched on 21 January 2020.Eligibility criteriaOnly quantitative studies were included. Single studies with fewer than 50 participants, published before 2014 and looking at outcomes which are not prioritised in the PIONEER core outcome set were excluded.Data extraction and synthesisAfter initial screening, we extracted data following the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of prognostic factor studies (CHARMS-PF) criteria and discussed the identified factors with a multidisciplinary expert group. The quality of the included papers was scored for applicability and risk of bias using validated tools such as PROBAST, Quality in Prognostic Studies and Quality Assessment of Diagnostic Accuracy Studies 2.ResultsThe search identified 6604 studies, from which 489 DPFs were included. Sixty-four of those were internally or externally validated. However, only three studies on diagnostic and seven studies on prognostic factors had a low risk of bias and a low risk concerning applicability.ConclusionMost of the DPFs identified require additional evaluation and validation in properly designed studies before they can be recommended for use in clinical practice. The PIONEER online search tool for DPFs for PCa will enable researchers to understand the quality of the current research and help them design future studies.Ethics and disseminationThere are no ethical implications.

Published
2022

5. Introducing PIONEER: a project to harness big data in prostate cancer research

Author

Omar M. I., Roobol M. J., Ribal M. J., Abbott T., Agapow P. -M., Araujo S., Asiimwe A., Auffray C., Balaur I., Beyer K., Bernini C., Bjartell A., Briganti A., Butler-Ransohoff J. -E., Campi R., Cavelaars M., De Meulder B., Devecseri Z., Voss M. D., Dimitropoulos K., Evans-Axelsson S., Franks B., Fullwood L., Horgan D., Smith E. J., Kiran A., Kivinummi K., Lambrecht M., Lancet D., Lindgren P., MacLennan S., Nogueira M. M., Moen F., Moinat M., Papineni K., Reich C., Reiche K., Rogiers S., Sartini C., van Bochove K., van Diggelen F., Van Hemelrijck M., Van Poppel H., Zong J., N'Dow J., Andersson E., Arala H., Auvinen A., Bangma C., Burke D., Cardone A., Casariego J., Cuperus G., Dabestani S., Esperto F., Fossati N., Fridhammar A., Gandaglia G., Tandefelt D. G., Horn F., Huber J., Hugosson J., Huisman H., Josefsson A., Kilkku O., Kreuz M., Lardas M., Lawson J., Lefresne F., Lejeune S., Longden-Chapman E., McVie G., Moris L., Mottet N., Murtola T., Nicholls C., Pang K. H., Pascoe K., Picozzi M., Plass K., Pohjanjousi P., Reaney M., Remmers S., Robinson P., Schalken J., Schravendeel M., Seisen T., Servan A., Shiranov K., Snijder R., Steinbeisser C., Taibi N., Talala K., Tilki D., Van den Broeck T., Vassilev Z., Voima O., Vradi E., Waldeck R., Weistra W., Willemse P. -P., Wirth M., Wolfinger R., Kermani N. Z., Omar, M. I., Roobol, M. J., Ribal, M. J., Abbott, T., Agapow, P. -M., Araujo, S., Asiimwe, A., Auffray, C., Balaur, I., Beyer, K., Bernini, C., Bjartell, A., Briganti, A., Butler-Ransohoff, J. -E., Campi, R., Cavelaars, M., De Meulder, B., Devecseri, Z., Voss, M. D., Dimitropoulos, K., Evans-Axelsson, S., Franks, B., Fullwood, L., Horgan, D., Smith, E. J., Kiran, A., Kivinummi, K., Lambrecht, M., Lancet, D., Lindgren, P., Maclennan, S., Nogueira, M. M., Moen, F., Moinat, M., Papineni, K., Reich, C., Reiche, K., Rogiers, S., Sartini, C., van Bochove, K., van Diggelen, F., Van Hemelrijck, M., Van Poppel, H., Zong, J., N'Dow, J., Andersson, E., Arala, H., Auvinen, A., Bangma, C., Burke, D., Cardone, A., Casariego, J., Cuperus, G., Dabestani, S., Esperto, F., Fossati, N., Fridhammar, A., Gandaglia, G., Tandefelt, D. G., Horn, F., Huber, J., Hugosson, J., Huisman, H., Josefsson, A., Kilkku, O., Kreuz, M., Lardas, M., Lawson, J., Lefresne, F., Lejeune, S., Longden-Chapman, E., Mcvie, G., Moris, L., Mottet, N., Murtola, T., Nicholls, C., Pang, K. H., Pascoe, K., Picozzi, M., Plass, K., Pohjanjousi, P., Reaney, M., Remmers, S., Robinson, P., Schalken, J., Schravendeel, M., Seisen, T., Servan, A., Shiranov, K., Snijder, R., Steinbeisser, C., Taibi, N., Talala, K., Tilki, D., Van den Broeck, T., Vassilev, Z., Voima, O., Vradi, E., Waldeck, R., Weistra, W., Willemse, P. -P., Wirth, M., Wolfinger, R., Kermani, N. Z., Publica, and Urology

Subjects
0301 basic medicine, Prioritization, Knowledge management, Urology, media_common.quotation_subject, education, Big data, Disease, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Multidisciplinary approach, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Medicine, Quality (business), media_common, business.industry, Patient-centered outcomes, medicine.disease, 3. Good health, Patient management, 030104 developmental biology, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], 030220 oncology & carcinogenesis, business
Abstract

Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. Launched by the Innovative Medicines Initiative 2 and part of the Big Data for Better Outcomes Programme (BD4BO), the overarching goal of PIONEER is to provide high-quality evidence on prostate cancer management by unlocking the potential of big data. The project has identified critical evidence gaps in prostate cancer care, via a detailed prioritization exercise including all key stakeholders. By standardizing and integrating existing high-quality and multidisciplinary data sources from patients with prostate cancer across different stages of the disease, the resulting big data will be assembled into a single innovative data platform for research. Based on a unique set of methodologies, PIONEER aims to advance the field of prostate cancer care with a particular focus on improving prostate-cancer-related outcomes, health system efficiency by streamlining patient management, and the quality of health and social care delivered to all men with prostate cancer and their families worldwide.Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. In this Perspectives article, the authors introduce the PIONEER project and describe its aims and plans for ultimately improving prostate cancer care through the use of big data.

Published
2020

6. Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research (Nature Reviews Urology, (2020), 17, 6, (351-362), 10.1038/s41585-020-0324-x)

Author

Omar M. I., Roobol M. J., Ribal M. J., Abbott T., Agapow P. -M., Araujo S., Asiimwe A., Auffray C., Balaur I., Beyer K., Bernini C., Bjartell A., Briganti A., Butler-Ransohoff J. -E., Campi R., Cavelaars M., De Meulder B., Devecseri Z., Voss M. D., Dimitropoulos K., Evans-Axelsson S., Franks B., Fullwood L., Horgan D., Smith E. J., Kiran A., Kivinummi K., Lambrecht M., Lancet D., Lindgren P., MacLennan S., Nogueira M. M., Moen F., Moinat M., Papineni K., Reich C., Reiche K., Rogiers S., Sartini C., van Bochove K., van Diggelen F., Van Hemelrijck M., Van Poppel H., Zong J., N'Dow J., Andersson E., Arala H., Auvinen A., Bangma C., Burke D., Cardone A., Casariego J., Cuperus G., Dabestani S., Esperto F., Fossati N., Fridhammar A., Gandaglia G., Tandefelt D. G., Horn F., Huber J., Hugosson J., Huisman H., Josefsson A., Kilkku O., Kreuz M., Lardas M., Lawson J., Lefresne F., Lejeune S., Longden-Chapman E., McVie G., Moris L., Mottet N., Murtola T., Nicholls C., Pang K. H., Pascoe K., Picozzi M., Plass K., Pohjanjousi P., Reaney M., Remmers S., Robinson P., Schalken J., Schravendeel M., Seisen T., Servan A., Shiranov K., Snijder R., Steinbeisser C., Taibi N., Talala K., Tilki D., Van den Broeck T., Vassilev Z., Voima O., Vradi E., Waldeck R., Weistra W., Willemse P. -P., Wirth M., Wolfinger R., Kermani N. Z., Omar, M. I., Roobol, M. J., Ribal, M. J., Abbott, T., Agapow, P. -M., Araujo, S., Asiimwe, A., Auffray, C., Balaur, I., Beyer, K., Bernini, C., Bjartell, A., Briganti, A., Butler-Ransohoff, J. -E., Campi, R., Cavelaars, M., De Meulder, B., Devecseri, Z., Voss, M. D., Dimitropoulos, K., Evans-Axelsson, S., Franks, B., Fullwood, L., Horgan, D., Smith, E. J., Kiran, A., Kivinummi, K., Lambrecht, M., Lancet, D., Lindgren, P., Maclennan, S., Nogueira, M. M., Moen, F., Moinat, M., Papineni, K., Reich, C., Reiche, K., Rogiers, S., Sartini, C., van Bochove, K., van Diggelen, F., Van Hemelrijck, M., Van Poppel, H., Zong, J., N'Dow, J., Andersson, E., Arala, H., Auvinen, A., Bangma, C., Burke, D., Cardone, A., Casariego, J., Cuperus, G., Dabestani, S., Esperto, F., Fossati, N., Fridhammar, A., Gandaglia, G., Tandefelt, D. G., Horn, F., Huber, J., Hugosson, J., Huisman, H., Josefsson, A., Kilkku, O., Kreuz, M., Lardas, M., Lawson, J., Lefresne, F., Lejeune, S., Longden-Chapman, E., Mcvie, G., Moris, L., Mottet, N., Murtola, T., Nicholls, C., Pang, K. H., Pascoe, K., Picozzi, M., Plass, K., Pohjanjousi, P., Reaney, M., Remmers, S., Robinson, P., Schalken, J., Schravendeel, M., Seisen, T., Servan, A., Shiranov, K., Snijder, R., Steinbeisser, C., Taibi, N., Talala, K., Tilki, D., Van den Broeck, T., Vassilev, Z., Voima, O., Vradi, E., Waldeck, R., Weistra, W., Willemse, P. -P., Wirth, M., Wolfinger, R., and Kermani, N. Z.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

7. Author Correction: Introducing PIONEER: A project to harness big data in prostate cancer research (Nature Reviews Urology, (2020), 17, 6, (351-362), 10.1038/s41585-020-0324-x)

Author

Omar, M.I., Roobol, M.J., Ribal, M.J., Abbott, T., Agapow, P.-M., Araujo, S., Asiimwe, A., Auffray, C., Balaur, I., Beyer, K., Bernini, C., Bjartell, A., Briganti, A., Butler-Ransohoff, J.-E., Campi, R., Cavelaars, M., Meulder, B. de, Devecseri, Z., Voss, M.D., Dimitropoulos, K., Evans-Axelsson, S., Franks, B., Fullwood, L., Horgan, D., Smith, E.J., Kiran, A., Kivinummi, K., Lambrecht, M., Lancet, D., Lindgren, P., MacLennan, S., Nogueira, M.M., Moen, F., Moinat, M., Papineni, K., Reich, C., Reiche, K., Rogiers, S., Sartini, C., Bochove, K. van, Diggelen, F. van, Hemelrijck, M. van, Poppel, H. van, Zong, J., N'Dow, J., Horn, F., Kreuz, M., and Publica

Abstract

The originally published article contained errors in Figure 1 and did not reflect the current organization of the PIONEER consortium. The figure has been corrected in the HTML and PDF versions of the manuscript to reflect the correct organization of PIONEER.

Published
2020

8. PIONEER: European Commission Innovative Medicines Initiative funded BD4BO (Big data for better outcome) project on prostate cancer

Author

Evans Axelsson, S., primary, Abbott, T., additional, Fullwood, L., additional, Omar, M.I., additional, Cavelaars, M., additional, Asiimwe, A., additional, Roobol, M., additional, Ribal, M.J., additional, Auffray, C., additional, Devecseri, Z., additional, Smith, E.J., additional, Van Hemelrijck, M., additional, MacLennan, S., additional, Horgan, D., additional, Reich, C., additional, De Meulder, B., additional, Lancet, D., additional, Bangma, C., additional, Briganti, A., additional, Tilki, D., additional, Van Poppel, H., additional, Wirth, M.P., additional, N’Dow, J., additional, and Bjartell, A., additional

Published
2020
Full Text
View/download PDF

11. Diagnostic and prognostic factors in patients with prostate cancer

Author

Antonella Cardone, Nicolas Mottet, Lisa Moris, Michael Lardas, Anna Haire, Francesco Barletta, Simone Scuderi, Eleni Vradi, Giorgio Gandaglia, Steven MacLennan, Bahman Farahmand, Sara J Maclennan, Zsuzsanna Devecseri, Alex Asiimwe, Laurence Collette, Anders Bjartell, James Ndow, James N'Dow, Karin Plass, Maria Ribal, Thomas Van den Broeck, Peter-Paul Willemse, Karl H Pang, Riccardo Campi, Isabella Greco, Mauro Gacci, Sergio Serni, Susan Evans-Axelsson, Ragnar Lonnerbro, Daniele Crosti, Massimiliano Meoni, Roberto Garzonio, Chris Bangma, Monique Roobol, Sebastiaan Remmers, Derya Tilki, Teemu Murtola, Tapio Visakorpi, Kirsi Talala, Teuvo Tammela, Aino Siltari, Stephane Lejeune, Femke van Diggelen, Georgia Taxiarchopoulou, Ketharini Senthilkumar, Stefanie Schütte, Sophie Byrne, Luz Fialho, Paulina Gono, Monica De Vetter, Klevisa Ceke, Bertrand De Meulder, Charles Auffray, Irina-Afrodita Balaur, Nesrine Taibi, Shaun Power, Nazanin Zounemat Kermani, Kees van Bochove, Marinel Cavelaars, Maxim Moinat, Emma Voss, Chiara Bernini, Denis Horgan, Louise Fullwood, Marc Holtorf, Doron Lancet, Gabi Bernstein, Imran Omar, Sara MacLennan, Jemma Healey, Johannes Huber, Manfred Wirth, Michael Froehner, Beate Brenner, Angelika Borkowetz, Christian Thomas, Friedemann Horn, Kristin Reiche, Markus Kreuz, Andreas Josefsson, Delila Gasi Tandefelt, Jonas Hugosson, Jack Schalken, Henkjan Huisman, Thomas Hofmarcher, Emelie Andersson, Adam Fridhammar, Frank Verholen, John-Edward Butler-Ransohoff, Todd Williamson, Kumari Chandrawansa, Dorothy Dlamini, Reg Waldeck, Megan Molnar, Amanda Bruno, Ronald Herrera, Ekaterina Nevedomskaya, Niculae Constantinovici, Carl Steinbeißer, Sini Thomas, Monika Maass, Patrizia Torremante, Marc Dietrich Voss, Guido Cuperus, Chad Dau Kishore, Papineni Jing, Wang-silvanto Steve, Hass Robert, Snijder Verena, Doyé Xuewei, Wang Andy Garnham, Mark Lambrecht, Russ Wolfinger, Stijn Rogiers, Angela Servan, Florence Lefresne, Joaquin Casariego, Mohamed Samir, Joe Lawson, Katie Pascoe, Bertrand Jaton, Daniel Bakkard, Heidi Turunen, Olavi Kilkku, Pasi Pohjanjousi, Olli Voima, Liina Nevalaita, Sonia Araujo, Elaine Longden-Chapman, Gordon McVie, Danny Burke, Paul Agapow, Sahra Derkits, Muriel Licour, Charles McCrea, Sarah Payne, Alan Yong, Flavia Lujan, Billy Franks, Michael Bussmann, Inken Köhle, Urology, Beyer, K., Moris, L., Lardas, M., Haire, A., Barletta, F., Scuderi, S., Vradi, E., Gandaglia, G., Omar, M. I., Maclennan, S., Zong, J., Farahmand, B., Maclennan, S. J., Devecseri, Z., Asiimwe, A., Collette, L., Bjartell, A., Ndow, J., Briganti, A., and Van Hemelrijck, M.

Subjects
Male, medicine.medical_specialty, Urological tumours, Urology, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Prostate disease, Bias, SDG 3 - Good Health and Well-being, Multidisciplinary approach, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Medicine, Humans, Medical physics, In patient, 030212 general & internal medicine, Protocol (science), Diagnostic Factor, urological tumours, business.industry, Quality assessment, Prostatic Neoplasms, General Medicine, medicine.disease, Prognosis, 3. Good health, Europe, Systematic review, Oncology, 030220 oncology & carcinogenesis, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], oncology, Model risk, business, prostate disease, Systematic Reviews as Topic
Abstract

IntroductionAs part of the PIONEER (Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe) Consortium, we will explore which diagnostic and prognostic factors (DPFs) are currently being researched to previously defined clinical and patient-reported outcomes for prostate cancer (PCa).Methods and analysisThis research project will follow the following four steps: (1) a broad systematic literature review of DPFs for all stages of PCa, covering evidence from 2014 onwards; (2) discussion of systematic review findings by a multidisciplinary expert panel; (3) risk of bias assessment and applicability with Prediction model Risk Of Bias Assessment Tool criteria, Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) and the Quality In Prognosis Studies tool (QUIPS) and (4) additional quantitative assessments if required.Ethics and disseminationWe aim to develop an online tool to present the DPFs identified in this research and make them available across all stakeholders. There are no ethical implications.

Published
2021

12. Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium.

Author

Omar MI, MacLennan S, Ribal MJ, Roobol MJ, Dimitropoulos K, van den Broeck T, MacLennan SJ, Axelsson SE, Gandaglia G, Willemse PP, Mastris K, Ransohoff JB, Devecseri Z, Abbott T, De Meulder B, Bjartell A, Asiimwe A, and N'Dow J

Subjects
Male, Humans, Consensus, Treatment Outcome, Europe, Prostatic Neoplasms diagnosis, Prostatic Neoplasms therapy
Abstract

PIONEER is a European network of excellence for big data in prostate cancer consisting of 37 private and public stakeholders from 9 countries across Europe. Many progresses have been done in prostate cancer management, but unanswered questions in the field still exist, and big data could help to answer these questions. The PIONEER consortium conducted a two-round modified Delphi survey aiming at building consensus between two stakeholder groups - health-care professionals and patients with prostate cancer - about the most important questions in the field of prostate cancer to be answered using big data. Respondents were asked to consider what would be the effect of answering the proposed questions on improving diagnosis and treatment outcomes for patients with prostate cancer and to score these questions on a scale of 1 (not important) to 9 (critically important). The mean percentage of participants who scored each of the proposed questions as critically important was calculated across the two stakeholder groups and used to rank the questions and identify the highest scoring questions in the critically important category. The identification of questions in prostate cancer that are important to various stakeholders will help the PIONEER consortium to provide answers to these questions to improve the clinical care of patients with prostate cancer., (© 2023. Springer Nature Limited.)

Published
2023
Full Text
View/download PDF

13. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium.

Author

Beyer K, Moris L, Lardas M, Omar MI, Healey J, Tripathee S, Gandaglia G, Venderbos LDF, Vradi E, van den Broeck T, Willemse PP, Antunes-Lopes T, Pacheco-Figueiredo L, Monagas S, Esperto F, Flaherty S, Devecseri Z, Lam TBL, Williamson PR, Heer R, Smith EJ, Asiimwe A, Huber J, Roobol MJ, Zong J, Mason M, Cornford P, Mottet N, MacLennan SJ, N'Dow J, Briganti A, MacLennan S, and Van Hemelrijck M

Subjects
Consensus, Humans, Male, Orchiectomy, Outcome Assessment, Health Care, Prostatic Neoplasms, Castration-Resistant
Abstract

Context: Harmonisation of outcome reporting and definitions for clinical trials and routine patient records can enable health care systems to provide more efficient outcome-driven and patient-centred interventions. We report on the work of the PIONEER Consortium in this context for prostate cancer (PCa)., Objective: To update and integrate existing core outcome sets (COS) for PCa for the different stages of the disease, assess their applicability, and develop standardised definitions of prioritised outcomes., Evidence Acquisition: We followed a four-stage process involving: (1) systematic reviews; (2) qualitative interviews; (3) expert group meetings to agree standardised terminologies; and (4) recommendations for the most appropriate definitions of clinician-reported outcomes., Evidence Synthesis: Following four systematic reviews, a multinational interview study, and expert group consensus meetings, we defined the most clinically suitable definitions for (1) COS for localised and locally advanced PCa and (2) COS for metastatic and nonmetastatic castration-resistant PCa. No new outcomes were identified in our COS for localised and locally advanced PCa. For our COS for metastatic and nonmetastatic castration-resistant PCa, nine new core outcomes were identified., Conclusions: These are the first COS for PCa for which the definitions of prioritised outcomes have been surveyed in a systematic, transparent, and replicable way. This is also the first time that outcome definitions across all prostate cancer COS have been agreed on by a multidisciplinary expert group and recommended for use in research and clinical practice. To limit heterogeneity across research, these COS should be recommended for future effectiveness trials, systematic reviews, guidelines and clinical practice of localised and metastatic PCa., Patient Summary: Patient outcomes after treatment for prostate cancer (PCa) are difficult to compare because of variability. To allow better use of data from patients with PCa, the PIONEER Consortium has standardised and recommended outcomes (and their definitions) that should be collected as a minimum in all future studies., (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)

Published
2022
Full Text
View/download PDF

14. Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol.

Author

Beyer K, Moris L, Lardas M, Haire A, Barletta F, Scuderi S, Vradi E, Gandaglia G, Omar MI, MacLennan S, Zong J, Farahmand B, Maclennan SJ, Devecseri Z, Asiimwe A, Collette L, Bjartell A, Ndow J, Briganti A, and Van Hemelrijck M

Subjects
Bias, Europe, Humans, Male, Prognosis, Systematic Reviews as Topic, Prostatic Neoplasms diagnosis
Abstract

Introduction: As part of the PIONEER (Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe) Consortium, we will explore which diagnostic and prognostic factors (DPFs) are currently being researched to previously defined clinical and patient-reported outcomes for prostate cancer (PCa)., Methods and Analysis: This research project will follow the following four steps: (1) a broad systematic literature review of DPFs for all stages of PCa, covering evidence from 2014 onwards; (2) discussion of systematic review findings by a multidisciplinary expert panel; (3) risk of bias assessment and applicability with Prediction model Risk Of Bias Assessment Tool criteria, Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) and the Quality In Prognosis Studies tool (QUIPS) and (4) additional quantitative assessments if required., Ethics and Dissemination: We aim to develop an online tool to present the DPFs identified in this research and make them available across all stakeholders. There are no ethical implications., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.)

Published
2021
Full Text
View/download PDF

15. Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research.

Author

Omar MI, Roobol MJ, Ribal MJ, Abbott T, Agapow PM, Araujo S, Asiimwe A, Auffray C, Balaur I, Beyer K, Bernini C, Bjartell A, Briganti A, Butler-Ransohoff JE, Campi R, Cavelaars M, De Meulder B, Devecseri Z, Voss MD, Dimitropoulos K, Evans-Axelsson S, Franks B, Fullwood L, Horgan D, Smith EJ, Kiran A, Kivinummi K, Lambrecht M, Lancet D, Lindgren P, MacLennan S, MacLennan S, Nogueira MM, Moen F, Moinat M, Papineni K, Reich C, Reiche K, Rogiers S, Sartini C, van Bochove K, van Diggelen F, Van Hemelrijck M, Van Poppel H, Zong J, and N'Dow J

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020
Full Text
View/download PDF

16. Introducing PIONEER: a project to harness big data in prostate cancer research.

Author

Omar MI, Roobol MJ, Ribal MJ, Abbott T, Agapow PM, Araujo S, Asiimwe A, Auffray C, Balaur I, Beyer K, Bernini C, Bjartell A, Briganti A, Butler-Ransohoff JE, Campi R, Cavelaars M, De Meulder B, Devecseri Z, Voss MD, Dimitropoulos K, Evans-Axelsson S, Franks B, Fullwood L, Horgan D, Smith EJ, Kiran A, Kivinummi K, Lambrecht M, Lancet D, Lindgren P, MacLennan S, MacLennan S, Nogueira MM, Moen F, Moinat M, Papineni K, Reich C, Reiche K, Rogiers S, Sartini C, van Bochove K, van Diggelen F, Van Hemelrijck M, Van Poppel H, Zong J, and N'Dow J

Subjects
Humans, Male, Big Data, Biomedical Research, Prostatic Neoplasms
Abstract

Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. Launched by the Innovative Medicines Initiative 2 and part of the Big Data for Better Outcomes Programme (BD4BO), the overarching goal of PIONEER is to provide high-quality evidence on prostate cancer management by unlocking the potential of big data. The project has identified critical evidence gaps in prostate cancer care, via a detailed prioritization exercise including all key stakeholders. By standardizing and integrating existing high-quality and multidisciplinary data sources from patients with prostate cancer across different stages of the disease, the resulting big data will be assembled into a single innovative data platform for research. Based on a unique set of methodologies, PIONEER aims to advance the field of prostate cancer care with a particular focus on improving prostate-cancer-related outcomes, health system efficiency by streamlining patient management, and the quality of health and social care delivered to all men with prostate cancer and their families worldwide.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results